READ-ONLY DIGITIZATION RESULT
Upfront Modified FOLFOXIRI Plus Panitumumab for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Results of the Phase III TRIPLETE Study.
J Clin Oncol · 2026-Feb-10 · PMID 41505697
Panel Kaplan-Meier_estimates_of_PPS_in_the_intention-to-treat_population提取完成待 EXE 对齐验证
PPS
FIG A3. Kaplan-Meier estimates of PPS in the intention-to-treat population, according to treatment groups. The control group indicates FOLFOX plus panitumumab. The experimental group indicates mFOLFOXIRI plus panitumumab. FOLFOX, fluorouracil, leucovorin, oxaliplatin; HR, hazard ratio; mFOLFOXIRI, modified fluorouracil, leucovorin, oxaliplatin, irinotecan; PPS, postprogression survival.
算法:legacy-0.5.0引擎:enhanced-linux
曲线数据
网页最多预览 200 行,完整数据请下载 CSV 或 JSON。
当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)
重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。
| 版本 | 状态 | 验证 | 曲线 | 时间 |
|---|---|---|---|---|
| legacy-0.5.0 | complete | 待验证 | 2 | 2026-07-18T19:28:23+00:00 |